SING (Study of Insulin & Glyburide) Study
SPONSOR:
Magee-Womens Foundation
PARTICIPATION:
Women with gestational diabetes between 24 and 34 weeks gestational age who are candidates for insulin therapy are eligible for this study.
DESCRIPTION:
The purpose of this clinical trial is to compare the effect of the oral hypoglycemic agent glyburide to conventional subcutaneous insulin therapy on neonatal body composition using non-invasive measurements and maternal glycemic control in women with gestational diabetes.
Gestational diabetes is glucose intolerance that is first recognized during pregnancy and affects approximately 4% of pregnancies in the United States. The goal for treatment in women with gestational diabetes is normal blood sugars and generally is achieved with diet and/or subcutaneous insulin administered 1-4 times daily. An equivalent oral alternative to standard insulin therapy may be a preferable treatment for many women secondary to overall patient compliance, convenience, and satisfaction.
If you are interested in or have any questions regarding the above study, please call:
412-641-4214.